Cure Pharmaceutical Buys Therapix Assets

Cure Pharmaceutical in Oxnard announced Wednesday that it has signed a term agreement for the acquisition of the non-pain assets of Therapix Biosciences Ltd., a clinical-stage pharmaceutical company that is developing cannabinoid-based medications.

The assets include several of Tel Aviv-based Therapix’s clinical drug candidates as well as two pre-clinical drug candidates, according to a statement from Cure. The acquisition will allow Cure to directly integrate Therapix’s clinical programs into the development of its proprietary oral thin film drug delivery platform. Therapix will become a significant shareholder in Cure as a result; its Chief Executive Dr. Ascher Schmulewitz will join Cure’s more at